Hydroxylated analogs of mexiletine as tools for structural-requirements investigation of the sodium channel blocking activity

Archiv der Pharmazie

Volumn 343, Issue 6, 2010, Pages 325-332

  Catalano, Alessia ^a   Carocci, Alessia ^a   Cavalluzzi, Maria M ^a   Di Mola, Antonia ^a   Lentini, Giovanni ^a   Lovece, Angelo ^a   Dipalma, Antonella ^a   Costanza, Teresa ^a   Desaphy, Jean François ^a   Camerino, Diana Conte ^a   Franchini, Carlo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Hydroxylation; Ion channel; Mexiletine

Indexed keywords

4 (2 AMINOPROPOXY) 3 (HYDROXYMETHYL) 5 METHYLPHENOL; [2 (2 AMINOPROPOXY) 1,3 PHENYLENE]DIMETHANOL; ANTIARRHYTHMIC AGENT; BETA 2 ADRENERGIC RECEPTOR; CLENBUTEROL; ION CHANNEL; LIGAND; MEXILETINE; NADOLOL; PROPRANOLOL; SALBUTAMOL; SODIUM CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ARTICLE; BINDING SITE; CELL STRAIN HEK293; DRUG HYDROXYLATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSPORT; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HYDROXYLATION; PATCH CLAMP; PRIORITY JOURNAL; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION;

ANTI-ARRHYTHMIA AGENTS; BINDING SITES; CELL LINE; DRUG DESIGN; HUMANS; HYDROXYLATION; MEXILETINE; MUSCLE, SKELETAL; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953504194     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900218     Document Type: Article

References (26)

1. A. Termin, E. Martinborough, D. Wilson, Annu. Rep. Med. Chem. 2008, 43, 43-60.
2. P. E. Fenster, K. A. Comess, Pharmacotherapy 1986, 6, 1-9.
3. R. Rüdel, F. Lehmann-Horn, Physiol. Rev. 1985, 65, 310-352.
4. W. A. Catterall, Trends Pharmacol. Sci. 1996, 19, 3-10.
5. E. Kalso, M. R. Tramèr, H. J. McQuay, R. A. Moore, Eur. J. Pain 1998, 2, 3-14.
6. J.-F. Desaphy, S. Pierno, A. De Luca, P. Didonna, D. Conte Camerino, Mol. Pharmacol. 2003, 63, 659-670.
7. A. Catalano, A. Carocci, G. Fracchiolla, C. Franchini, et al., Chirality 2004, 16, 72-78.
8. M. De Bellis, A. De Luca, F. Rana, M. M. Cavalluzzi, et al., Br. J. Pharmacol. 2006, 149, 300-310.
9. M. M. Cavalluzzi, A. Catalano, C. Bruno, A. Lovece, et al., Tetrahedron Asymmetry 2007, 18, 2409-2417.
10. A. Carocci, A. Catalano, F. Corbo, A. Duranti, et al., Tetrahedron Asymmetry 2000, 11, 3619-3634.
11. A. K. Bose, F. Greer, C. C. Price, J. Org. Chem. 1958, 23, 1335-1338.
12. O. Mitsunobu, Synthesis 1981, 1.
13. F. B. Mallory, M. J. Rudolph, S. M. Oh, J. Org. Chem. 1989, 54, 4619-4626.
14. H.-J. Buysch, E.-G. Hoffmann, U. Jansen, D. Ooms, B.-U. Schenke, D.E. Patent 19520612, 1996; Chem. Abstr. 1997, 126, 59733.
15. E. Roubini, R. Laufer, C. Gilon, Z. Selinger, et al., J. Med. Chem. 1991, 34, 2430-2438.
16. A. Adejare, S. S. Sciberras, Pharm. Res. 1997, 14, 533-535.
17. I. K. Boddy, R. C. Cambie, G. Dixon, P. S. Rutledge, P. D. Woodgate, Aust. J. Chem. 1983, 36, 803-813.
18. D. Kikuchi, S. Sakaguchi, Y. Ishii, J. Org. Chem. 1998, 63, 6023-6026.
19. D. S. Ragsdale, J. C. McPhee, T. Scheuer, W. A. Catterall, Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 9270-9275.
20. A. De Luca, F. Natuzzi, J.-F. Desaphy, G. Loni, et al., Mol. Pharmacol. 2000, 57, 268-277.
21. W. C. Still, M. Kahn, A. Mitra, J. Org. Chem. 1978, 43, 2923-2925.
22. J. E. Comer, K. Y. Tam in Pharmacokinetic Optimization in Drug Research, (Eds.: B. Testa, H. van de Waterbeemd, G. Folkers, R. H. Guy), Wiley-VCH, Zürich, Switzerland, 2001, pp. 275-304.
23. A. Avdeef, Quant. Struct.-Act. Relat. 1992, 11, 510-517.
24. A. Avdeef, J. Pharm. Sci. 1993, 82, 183-190.
25. A. Avdeef in Lipophilicity in Drug Action and Toxicology, (Eds.: V. Pilska, B. Testa, H. van de Waterbeemd), VCH Publishers, Weinheim, Germany, 1996, pp. 109-139.
26. A. Avdeef, K. J. Box, J. E. Comer, M. Gilges, et al., J. Pharm. Biomed. Anal. 1999, 20, 631-641.